
VERAXA Biotech Completes Business Combination, Begins Trading on Nasdaq
VERAXA Biotech has closed its business combination with Voyager Acquisition Corp., enabling it to trade on Nasdaq and advance its bispecific T-cell engagers and antibody-drug conjugates toward clinical development.
Read full story
























